timothy sykes logo
LEGN Stock Drops As UBS Slashes Price Target On Carvykti Fears Thumbnail
G Google News

LEGN Stock Drops As UBS Slashes Price Target On Carvykti Fears

BRYCE TUOHEY•UPDATED JUL. 27, 2026, 12:34 PM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Legend Biotech Corporation stocks have been trading down by -13.97 percent amid negative sentiment surrounding its latest clinical trial developments.

Key Takeaways

  • UBS cut Legend Biotech to Neutral from Buy and slashed its price target to $28 from $49.
  • The downgrade centers on weaker-than-expected growth for Legend Biotech’s flagship cell therapy Carvykti.
  • UBS now sees a smaller market opportunity as Anito-cel, Tecvayli, and Talvey crowd the multiple myeloma space.
  • Recent price action shows LEGN breaking down from the high-$20s into the teens, signaling shaken confidence.

Candlestick Chart

Live Update At 12:32:49 EDT: On Monday, July 27, 2026 Legend Biotech Corporation stock [NASDAQ: LEGN] is trending down by -13.97%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Legend Biotech Corporation, ticker LEGN, is trading like a growth story being repriced. In early July, LEGN was holding near $30, closing around $29.91 on 2026/07/02. From there, the stock started to leak lower day after day. By 2026/07/24, just as UBS moved LEGN to Neutral and slashed its target to $28, the stock closed near $22.22. On 2026/07/27, LEGN finished at $19.11, a sharp breakdown from that $30 area earlier in the month.

For traders, that’s a big reset — roughly a one‑third slide in a few weeks. Intraday action on the latest session shows heavy volatility: LEGN opened strong near $20.58, spiked to $20.80, then sold off hard toward $19 and churned around that level all day. That pattern screams distribution, not accumulation.

More Breaking News

Fundamentally, Legend Biotech posted about $627.2M in revenue, yet key profitability metrics are deep in the red, with negative returns on assets and equity. The price‑to‑sales ratio near 3.1 says the market still prices LEGN as a serious growth biotech, but the charts are now questioning how fast that growth will actually show up.

Why Traders Are Watching LEGN Now

Legend Biotech is back in the spotlight because UBS just threw cold water on the Carvykti story. The firm cut LEGN from Buy to Neutral and chopped its price target from $49 down to $28. That is not a minor trim — it’s a reset. UBS is basically telling the market that its old growth assumptions for Carvykti were too optimistic.

Carvykti is the key asset for Legend Biotech. LEGN has been treated as a high‑potential cell therapy name, with traders betting on rapid uptake in multiple myeloma. UBS is now flagging weaker‑than‑expected growth for Carvykti and saying the market opportunity is smaller than it once modeled. The reason: rising competition. Anito‑cel, Tecvayli, and Talvey are crowding into the same disease space, giving doctors and patients multiple options.

For traders, that competitive pressure matters more than any slide deck. When an analyst slashes a target on LEGN from $49 to $28, it often triggers forced re‑rating across funds and systematic strategies. That aligns with what we see on the tape: LEGN’s steady drift from the $30 zone down through the low‑$20s and now sub‑$20 as the downgrade hits.

The intraday chart shows LEGN trying to bounce early, failing near $20.80, then grinding lower with repeated pushes under $19. There are small bounces, but no real trend reversal. That’s classic “sell the news” behavior after a harsh Wall Street downgrade.

Active traders should view this as a sentiment break in Legend Biotech. LEGN is still a real company with over $1.67B in assets and more than $286.7M in cash, plus a sizable working capital cushion. But in this market, story stocks trade on trajectory, not just balance sheets. Right now, UBS is saying that trajectory for Carvykti looks flatter, and the chart for LEGN is echoing that message.

Conclusion

Legend Biotech traders are dealing with a clear narrative shift. LEGN went from a $30 name that the Street loved to a sub‑$20 stock facing tough questions about its flagship therapy. UBS cutting Legend Biotech to Neutral and hacking the target to $28 from $49 tells traders that big money is no longer willing to pay up for the same Carvykti growth story.

The key for LEGN from here is proof. Legend Biotech will need data, demand, and sales trends that show Carvykti can still carve out meaningful share despite Anito‑cel, Tecvayli, and Talvey pressing in. Until that shows up, many firms will treat LEGN as a wait‑and‑see trade rather than a must‑own biotech growth play.

For short‑term traders, this kind of breakdown can still offer opportunity. LEGN’s volatility, sharp gaps, and intraday swings around $19 create clear levels to plan around. But these are trades, not long‑term commitments. As Tim Sykes likes to remind his community, “Patterns repeat, but only for traders who are prepared, disciplined, and always ready to cut losses fast.” As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. Legend Biotech now sits in that pattern‑rich, high‑risk, high‑emotion zone — a place where smart traders stay nimble, respect risk, and let the price action confirm the next move.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”